Enteric coated risedronate 35mg for the treatment of osteoporosis

Description

In this Product Explainer, Endocrinologist Prof Ego Seeman explains the role of enteric coated risedronate 35mg for the treatment of osteoporosis (5 mins).

Icon 2

NEXT LIVE Webcast

:
Days
:
Hours
:
Minutes
Seconds
Dr Marie-Claire Seeley

Dr Marie-Claire Seeley

Postural Orthostatic Tachycardia Syndrome in Women

Dr Charlotte Hespe & Dr Ramy Bishay

Dr Charlotte Hespe & Dr Ramy Bishay

Panel Discussion on The Role of GLP-1 in the Management of CKD in T2D

Dr Anthony Chitti

Dr Anthony Chitti

Big Heads & Small Heads

Dr Sam Mehr

Dr Sam Mehr

Peanut Allergy

Join us for the next free webcast for GPs and healthcare professionals

High quality lectures delivered by leading independent experts

Prof Ego Seeman

expert

Prof Ego Seeman

Endocrinologist; Dept of Medicine and Endocrinology, Austin Health, University of Melbourne; Editor, Progress in Osteoporosis

Date published: 7 November 2023